Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT

Study Overview
=================
Brief Summary
-----------------
This is a retrospective analysis of a homogeneous cohort of patients with relapsed/refractory HL that received IGEV scheme as induction therapy to HDCT and AHSCT for reassess the most common prognostic factors and try to identify a prognostic score with clinical and therapeutic relevance by using 6 clinical tools: B symptoms(yes/no) relapse in previously irradiated areas(yes/no) Ann Arbor Stage (III/IV vs I/II) disease status at accrual (refractory vs relapsed) Early relapse within 12 months of Complete Response (CR) versus late relapse after Complete Response (CR) lasting > l2 months, extranodal involvement (yes/no).

Official Title
-----------------
Prognosis of Patients With Relapsed/Refractory Hl Treated With Combination of Ifosfamide, Gemcitabine and Vinorelbine(IGEV) Induction Therapy Before High-dose Chemotherapy (HDCT) With Autologous Hematopoietic Stem Cells Transplantation (AHSCT)

Conditions
-----------------
Hodgkin's Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a history of classical HL relapsed/refractory which received IGEV regimen as induction therapy before high dose chemotherapy with AHSCT Age >18 years Patients with relapsed/refractory disease after standard treatments (chemotherapy +/- radiotherapy) before IGEV induction regimen. (Relapsed = disease relapse after CR. Refractory = non CR with last chemotherapy line, or progression during last treatment, or disease progression within three months from previous treatment completion). Availability of clinical data, laboratory values and CT scan results of patients enrolled, performed from diagnosis to the last follow-up Patient scheduled to receive three or four IGEV cycles as pretransplantation induction regimen. First IGEV course started before December 31st 2007 Assessment of tumor response by Cheson 1999 criteria 11 Exclusion Criteria: NONE

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prognostic score will be defined taking into account Overall Survival (OS). | Surviving patents will be censored at the date of last known to be alive. | 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the defined prognostic score in terms of Progression Free Survival (PFS) | response rate in terms of Complete Response (CR) response rate in terms of Overall Response Rate (ORR) To validate the prognostic scores in terms of PFS and in terms OS | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hodgkin's Lymphoma, Ifosfamide, Gemcitabine and Vinorelbine (IGEV), High Dose Chemotherapy (HDCT), Autologous Hematopoietic Stem Cells Transplantation (AHSCT)